Products for Research Use Only

VPC-14228

CAT: 0804-HY-117669-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-117669-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
VPC-14228 is an inhibitor that selectively targets androgen receptor DNA binding domain (AR-DBD) . VPC-14228 inhibits the interaction between AR and DNA, thereby blocking AR-mediated transcriptional activation. VPC-14228 does not rely on nuclear localization inhibition, but rather inhibits the activity of full-length AR and splice variant AR-V7 by interfering with AR binding to chromatin. And VPC-14228 has high selectivity for other nuclear receptors such as ER and PR. VPC-14228 can be used in the study of prostate cancer[1][2].
CAS Number
19983-28-9
Product Name Alternative
21-desDFZ-d5, 21-desDFZ
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Androgen Receptor
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vpc-14228.html
Purity
99.36
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
N1(C2=NC(C3=CC=CC=C3)=CS2)CCOCC1
Molecular Formula
C13H14N2OS
Molecular Weight
246.33
Precautions
H302, H315, H319, H335
References & Citations
[1]Kush Dalal, et al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289 (38) :26417-26429.|[2]Bhumireddy A, et al. Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders. Bioorg Med Chem Lett. 2022 Jan 1;55:128448.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported